Enlivex Therapeutics .(ENLV) - 2021 Q4 - Annual Report

Exhibit 99.1 Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates ● Development of frozen formulation Allocetra™, a primary cornerstone of Enlivex's R&D ef orts during the last two years, was successfully completed in Q1 2022, twelve months ahead of schedule ● Frozen formulation Allocetra™ is expected to vastly improve the product's shelf-life, shipping logistics, and manufacturing scalabil ...